Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TBX201
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Chartered Group
Deal Size : $3.0 million
Deal Type : Series A Financing
Details : The proceeds are being utilized to advance the development of Trobix's cutting-edge proprietary platform technology and to advance Precision Microbiome Oncology Therapeutics including TBX201, an oral capsule designed to alter the gut microbiome.
Product Name : TBX201
Product Type : Microorganism
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : TBX201
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Chartered Group
Deal Size : $3.0 million
Deal Type : Series A Financing
Lead Product(s) : TBX101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Chartered Opus
Deal Size : $3.0 million
Deal Type : Series A Financing
Trobix Bio Completed Series A Funding by a Leading Japanese/Singapore Fund
Details : The funding will be used to advance the company’s antimicrobial resistance platform technology and to further the pre-clinical development of the its lead product, TBX101.
Product Name : TBX101
Product Type : Antibiotic
Upfront Cash : Undisclosed
July 29, 2020
Lead Product(s) : TBX101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Chartered Opus
Deal Size : $3.0 million
Deal Type : Series A Financing
Reset All
